JP Morgan Initiates Coverage On Cogent Biosciences with Overweight Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has initiated coverage on Cogent Biosciences with an Overweight rating and set a price target of $18 for the company's stock.

December 08, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cogent Biosciences receives an Overweight rating from JP Morgan with a price target of $18, indicating a positive outlook on the stock.
The initiation of coverage by a major financial institution like JP Morgan typically generates investor interest and can lead to increased buying pressure. The Overweight rating suggests that the analyst believes COGT has a better value proposition compared to other stocks in the sector. The price target of $18 implies a significant upside from current levels, which could attract investors looking for growth opportunities.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100